Anacor Pharmaceuticals Contract Details

Defense contract under the Defense Threat Reduction Agency awarded to Anacor Pharmaceuticals on 10/18/2013.

Per the U.S. DoD, * Indicates a "small business" classification and ** indicates a "small disadvantaged business". NOTE: the U.S. DoD only publicly reports contracts valued at $6.5 million USD or greater.

The contract language is EXACTLY as it appears on the official U.S. DoD website ( unless otherwise noted.

Contractor: Anacor Pharmaceuticals
Department: Defense Threat Reduction Agency
Awarded: 10/18/2013

Anacor Pharmaceuticals, Palo Alto, California, was awarded a maximum $13,495,328 cost-plus-fixed-fee contract in support of the Defense Threat Reduction Agency J9 Research and Development division. This contract is for research toward overcoming resistance by the application of boron to ribosomal inhibitors. Work will be performed in Palo Alto, California and is expected to be complete April 15, 2017. Fiscal 2013 research, development, test and evaluation funds in the amount of $2,756,968 were obligated at time of award. This contract was solicited by full and open competition and one offer was received. The Defense Threat Reduction Agency, Fort Belvoir, Va., is the contracting activity (HDTRA1-14-C-0003). (Awarded Oct. 16, 2013)

Total Contract Value: $13,495,328

View all contracts that include "Anacor Pharmaceuticals" in the MiC database.